# Absence Seizure

Confirm typical absence seizures with an event-capturing EEG, then classify childhood versus juvenile absence epilepsy and screen for myoclonic or generalized tonic-clonic seizures before selecting ethosuximide, valproate, or lamotrigine.

**Clinical question:** How should clinicians confirm, classify, treat, and monitor typical absence seizures across childhood and juvenile generalized epilepsy syndromes?

Updated: 2026-08-21T02:33:21.172314+00:00

## What matters in practice
- A brief behavioral arrest lasting about 5 to 10 seconds with little or no postictal confusion, especially when provoked by hyperventilation, should prompt EEG evaluation for typical absence seizures. [1]
- Regular, symmetric generalized 3-Hz spike-and-wave during a typical event supports typical absence seizures; the syndrome assignment depends on age at onset and coexisting generalized seizure types. [1][15]
- For childhood or juvenile absence epilepsy, ethosuximide and valproate have shown superior short-term efficacy to lamotrigine; ethosuximide is limited to absence-seizure control, whereas valproate covers generalized tonic-clonic and myoclonic seizures. [1][4][17]
- Adolescent-onset absences, generalized tonic-clonic seizures, morning myoclonus, generalized polyspike-wave, or photosensitivity should redirect classification toward juvenile absence epilepsy or juvenile myoclonic epilepsy. [16][21][24]
- Childhood absence epilepsy often remits by adulthood, but cognitive difficulty at diagnosis, absence status, later generalized tonic-clonic or myoclonic seizures, an abnormal EEG background, and first-degree family history of generalized seizures predict lower likelihood of remission. [1][23]

## Confirm an epileptic absence rather than a behavioral lapse

The decisive first step is correlation of a typical spell with EEG.

Obtain a first-hand witness history and, when available, smartphone video. Establish abrupt onset and offset, behavioral arrest, impaired responsiveness, duration, automatisms, precipitants, recovery, and any previous unrecognized events. Witness accounts and video can improve diagnostic accuracy; the before-during-after sequence is specifically useful for seizure-type discrimination. [22]

Typical absence seizures usually last approximately 5 to 10 seconds, have minimal or no postictal confusion, and are commonly precipitated by hyperventilation; photic stimulation can also precipitate events. A longer confusional recovery, focal onset features, or an event that is not abrupt should reduce confidence in typical absence seizures and broaden the event differential before assigning a generalized epilepsy syndrome. [1]

Order routine EEG with activation procedures and seek capture of the habitual clinical event. Typical absence seizures have regular, symmetric generalized spike-and-wave at about 3 Hz during the ictus. EEG interpretation should include background organization, discharge frequency, polyspike-wave morphology, and photic response because these features help distinguish childhood absence epilepsy from adolescent generalized epilepsy syndromes. [1][16]
- Document whether hyperventilation provokes the patient’s usual behavioral arrest and whether the concurrent EEG shows generalized spike-and-wave. [1]
- Ask specifically about generalized tonic-clonic seizures, jerks soon after awakening, and photic sensitivity; each changes both syndrome classification and medication selection. [16][21][24]
- Do not equate every staring episode with absence epilepsy: use electroclinical correlation rather than clinical appearance alone. [1][22]

*Electroclinical features that direct syndrome classification and next treatment decision. [1][15][16][21][24]*

| Pattern | Key discriminators | EEG pattern | Immediate implication |
| --- | --- | --- | --- |
| Childhood absence epilepsy | Otherwise normal child; onset generally age 4 to 10 years, with frequent daily absences and peak onset around 5 to 7 years. [11][12][15] | Normal background with generalized 2.5- to 4-Hz, commonly 3-Hz, spike-wave discharges. [15][16] | If absences are the only seizure type, consider ethosuximide; assess for seizures that would require broader coverage. [1][17] |
| Juvenile absence epilepsy | Onset around puberty or adolescence; absences commonly coexist with generalized tonic-clonic seizures and may coexist with myoclonus. [12][21][24] | Generalized spike-wave, often about 3 to 6 Hz; may be faster than childhood absence epilepsy. [16][21][24] | Avoid treating as isolated absence epilepsy when generalized tonic-clonic seizures are present; select a medication with broader generalized-seizure coverage. [21] |
| Juvenile myoclonic epilepsy | Myoclonic jerks commonly occur soon after waking; absence and generalized tonic-clonic seizures may also occur. [24] | Generalized 3.5- to 6-Hz polyspike-wave; photoparoxysmal response occurs in about one-third. [16] | Identify myoclonus before choosing absence-focused monotherapy; management must address the full generalized seizure phenotype. [16][24] |
| Atypical electroclinical presentation | Prolonged or nonabrupt events, meaningful post-event confusion, focal features, developmental concerns, or abnormal EEG background. [1][23] | Does not fit regular symmetric 3-Hz generalized spike-wave on a normal background. [1][16] | Reassess seizure classification and investigate alternative epilepsy syndromes or nonepileptic events before committing to syndrome-specific treatment. [1][22] |

## Classify the generalized epilepsy syndrome before choosing monotherapy

Age alone is insufficient; seizure inventory and EEG morphology determine the clinically relevant branch.

Childhood absence epilepsy is an idiopathic or genetic generalized epilepsy syndrome in an otherwise normal child with daily absence seizures and generalized spike-wave at 2.5 to 4 Hz. Commonly cited onset is age 4 to 10 years, with a peak at 5 to 7 years. A normal EEG background strengthens this classification; an abnormal background should prompt reconsideration because it is also associated with poorer long-term remission in typical childhood absence epilepsy cohorts. [11][12][15][16][23]

Juvenile absence epilepsy typically begins around puberty and is characterized by absences with generalized tonic-clonic seizures; some patients also have myoclonic jerks. Generalized spike-wave can range from 3 to 6 Hz, and a normal EEG does not by itself exclude juvenile absence epilepsy when the history is strongly typical. Because generalized tonic-clonic seizures are central to the syndrome phenotype, ethosuximide alone may leave clinically important seizure types untreated. [21]

Juvenile myoclonic epilepsy should be actively sought in adolescents with absence spells by asking about morning myoclonic jerks and generalized tonic-clonic seizures. Its EEG commonly shows generalized 3.5- to 6-Hz polyspike-wave, and photoparoxysmal response is reported in about one-third of patients. The absence presentation can precede readily apparent juvenile myoclonic epilepsy EEG features, so repeat clinical review for evolving myoclonus is important when the phenotype changes. [16][24]
- Childhood-onset, frequent daily absences plus normal background and approximately 3-Hz generalized spike-wave favors childhood absence epilepsy. [11][15][16]
- Pubertal onset or generalized tonic-clonic seizures favors juvenile absence epilepsy. [12][21][24]
- Morning myoclonus and generalized polyspike-wave favor juvenile myoclonic epilepsy. [16][24]
- An absence syndrome is not fully classified until the clinician has determined whether generalized tonic-clonic or myoclonic seizures are present. [1][21][24]

## Match antiseizure therapy to the complete seizure phenotype

Medication selection hinges on whether absence seizures occur in isolation or alongside other generalized seizure types.

For childhood absence epilepsy with absence seizures as the sole recognized seizure type, ethosuximide is a first-line option. It is identified as the optimal treatment option for new-onset childhood absence epilepsy in randomized dose-escalation work, and it is described as first-line therapy for childhood absence epilepsy. Its key tradeoff is narrow seizure-spectrum utility: the treatment choice must be revisited if generalized tonic-clonic or myoclonic seizures emerge. [19][20]

Valproate is an alternative first-line agent when the clinical history includes generalized tonic-clonic seizures or myoclonic seizures, because it treats generalized seizure phenotypes beyond absences. In a 14-week double-blind trial in childhood and juvenile absence epilepsy, valproate and ethosuximide were superior to lamotrigine; systematic review guidance similarly supports considering ethosuximide or valproate before lamotrigine for absence seizures. [1][4][17]

Lamotrigine is a reasonable alternative when ethosuximide or valproate is unsuitable, but clinicians should counsel that it had lower short-term efficacy than ethosuximide or valproate in comparative absence-epilepsy trials. In patients with a generalized epilepsy phenotype who could become pregnant, treatment selection requires individualized consideration of valproate risk-benefit tradeoffs; the reviewed pharmacology literature specifically identifies lamotrigine as a consideration in women. [4][17]

Do not infer that any antiseizure medication effective for focal epilepsy is appropriate for an absence syndrome. The treatment target is the diagnosed generalized epilepsy syndrome and its complete seizure inventory, not simply the presenting stare. Reassess the history after any breakthrough event, especially for generalized tonic-clonic seizures or morning myoclonus that would make ethosuximide monotherapy inadequate. [1][16][21]
- Isolated childhood absence phenotype: ethosuximide is a first-line option. [19][20]
- Absences plus generalized tonic-clonic or myoclonic seizures: favor an agent with broader generalized seizure coverage, such as valproate when clinically appropriate. [1][17][21]
- When choosing lamotrigine, account for lower comparative short-term efficacy for absence control versus ethosuximide or valproate. [4][17]
- No medication doses are specified here because the cited sources do not provide a regimen suitable for point-of-care prescribing; use current product labeling and epilepsy-specific dosing guidance.

*Medication selection by seizure phenotype. [1][4][17][19][20][21]*

| Clinical phenotype | Preferred treatment direction | Key limitation or tradeoff |
| --- | --- | --- |
| Childhood absence epilepsy with absences only | Ethosuximide is a first-line option for new-onset childhood absence epilepsy. [19][20] | Its role is absence-focused; emergence of generalized tonic-clonic or myoclonic seizures requires reassessment of coverage. [1][21] |
| Absence epilepsy with generalized tonic-clonic seizures | Consider valproate because treatment must cover the broader generalized seizure phenotype. [1][21] | Individualize valproate use, particularly in patients who could become pregnant; lamotrigine may be considered in women. [17] |
| Absence epilepsy with myoclonus or juvenile myoclonic epilepsy features | Use a regimen directed at the full generalized epilepsy syndrome rather than ethosuximide-only therapy. [16][24] | Polyspike-wave and morning myoclonus signal a syndrome branch different from isolated childhood absence epilepsy. [16][24] |
| Ethosuximide or valproate not suitable | Lamotrigine is an alternative option. [17] | Expect lower comparative short-term absence efficacy than ethosuximide or valproate. [4][17] |

## Monitor for seizure evolution and prognostic modifiers

Follow-up should detect persistent absences, treatment failure, and evolution into a broader generalized epilepsy syndrome.

At each follow-up, obtain event frequency from caregivers, teachers, and the patient; ask separately about unrecognized brief arrests, generalized tonic-clonic seizures, and early-morning myoclonus. Continued or newly recognized generalized tonic-clonic and myoclonic seizures alter the syndrome diagnosis and invalidate an absence-only treatment strategy. [1][21][24]

Use repeat EEG when clinical events persist, the seizure phenotype changes, or treatment response is uncertain. For childhood absence epilepsy, continued generalized spike-wave activity during a habitual event supports ongoing absence seizures; in juvenile absence epilepsy and juvenile myoclonic epilepsy, faster spike-wave or polyspike-wave patterns can clarify the syndrome branch. [1][16][21]

Counsel families that childhood absence epilepsy often remits by adulthood, but avoid presenting remission as assured. Factors associated with failure to remit include cognitive difficulties at diagnosis, absence status before or during antiseizure therapy, later generalized tonic-clonic or myoclonic seizures, abnormal initial EEG background, and a first-degree family history of generalized seizures. These findings justify more cautious long-term surveillance and repeat syndrome assessment. [1][23]
- Persistent absences despite treatment should trigger verification of adherence, repeat seizure history, and EEG reassessment rather than automatic escalation based on caregiver impression alone. [1][22]
- New generalized tonic-clonic seizures or morning myoclonus should prompt reclassification toward juvenile absence epilepsy or juvenile myoclonic epilepsy. [21][24]
- Cognitive difficulty, abnormal EEG background, absence status, and later generalized tonic-clonic or myoclonic seizures identify patients with less favorable remission expectations. [23]

## References
1. Absence seizures - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/115
2. Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II) | BMJ Open — bmjopen.bmj.com — https://bmjopen.bmj.com/content/10/8/e040635
3. 30 years of second-generation antiseizure medications — www.thelancet.com — https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30035-1/abstract
4. The SANAD II study of the effectiveness and cost ... — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00246-4/fulltext
5. When the first antiepileptic drug fails in a patient with ... — pn.bmj.com — https://pn.bmj.com/content/10/4/208
6. Recent Advances in the Treatment of Epilepsy — jamanetwork.com — https://jamanetwork.com/journals/jamaneurology/fullarticle/784359
7. Treatment of Newly Diagnosed Pediatric Epilepsy — jamanetwork.com — https://jamanetwork.com/journals/jamapediatrics/fullarticle/348283
8. Evolving Antiepileptic Drug Treatment in Juvenile ... — jamanetwork.com — https://jamanetwork.com/journals/jamaneurology/fullarticle/784514
9. New Antiepileptic Drugs | Epilepsy and Seizures — jamanetwork.com — https://jamanetwork.com/journals/jamaneurology/fullarticle/774204
10. Childhood Absence Epilepsy - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/childhood-absence-epilepsy
11. Childhood absence epilepsy: Elctroclinical features and diagnostic criteria - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0387760410000598
12. Childhood Absence Epilepsy - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/childhood-absence-epilepsy
13. Voltage-gated calcium channels in the etiopathogenesis and treatment of absence epilepsy - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0165017309001337
14. ILAE classification of the epilepsies: Position paper ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/epi.13709
15. ILAE definition of the Idiopathic Generalized Epilepsy ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/epi.17236
16. Outcome of Absence Epilepsy With Onset at 8-11... : Journal of Child Neurology — journals.lww.com — https://journals.lww.com/00004811-202338080-00003
17. Neuropharmacology of Antiseizure Drugs - Hakami - 2021 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/npr2.12196
18. Clinical and experimental insight into pathophysiology ... — academic.oup.com — https://academic.oup.com/brain/article/143/8/2341/5841645
19. Model‐Informed Precision Dosing Guidance of Ethosuximide ... — ascpt.onlinelibrary.wiley.com — https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2965
20. An innovative ethosuximide granule formulation designed for ... — bpspubs.onlinelibrary.wiley.com — https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.1032
21. Juvenile Absence Epilepsy - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK559055
22. Assessment | Diagnosis | Epilepsy | CKS | NICE — cks.nice.org.uk — https://cks.nice.org.uk/topics/epilepsy/diagnosis/assessment
23. Long-term prognosis of typical childhood absence epilepsy — www.neurology.org — https://www.neurology.org/doi/abs/10.1212/WNL.47.4.912
24. Epilepsies in children, young people and adults — www.nice.org.uk — https://www.nice.org.uk/guidance/ng217/documents/supporting-documentation-4

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.